Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DBT005
MIFTS: 55

Diabetes Insipidus

Categories: Endocrine diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Diabetes Insipidus

About this section

MalaCards integrated aliases for Diabetes Insipidus:

Name: Diabetes Insipidus 12 74 29 6 42 43 15 71 32

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Endocrine diseases Nephrological diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9409
ICD9CM 34 253.5
MeSH 43 D003919
NCIt 49 C43263
SNOMED-CT 67 15771004
ICD10 32 E23.2
UMLS 71 C0011848
Sources

Summaries for Diabetes Insipidus

About this section
MedlinePlus : 42 Diabetes insipidus (DI) causes frequent urination. You become extremely thirsty, so you drink. Then you urinate. This cycle can keep you from sleeping or even make you wet the bed. Your body produces lots of urine that is almost all water. DI is different from diabetes mellitus (DM), which involves insulin problems and high blood sugar. The symptoms can be similar. However, DI is related to how your kidneys handle fluids. It's much less common than DM. Urine and blood tests can show which one you have. Usually, DI is caused by a problem with your pituitary gland or your kidneys. Treatment depends on the cause of the problem. Medicines can often help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Insipidus is related to hereditary nephrogenic diabetes insipidus and diabetes insipidus, neurohypophyseal. An important gene associated with Diabetes Insipidus is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Glucose / Energy Metabolism. The drugs Dexmedetomidine and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and kidney, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Diabetes insipidus (DI) is a condition characterized by large amounts of dilute urine and increased... more...

Sources

Related Diseases for Diabetes Insipidus

About this section

Diseases in the Diabetes Insipidus family:

Hereditary Central Diabetes Insipidus Acquired Central Diabetes Insipidus

Diseases related to Diabetes Insipidus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 943)
# Related Disease Score Top Affiliating Genes
1 hereditary nephrogenic diabetes insipidus 34.7 AVPR2 AQP2
2 diabetes insipidus, neurohypophyseal 34.1 WFS1 PRL POMC OXT NPTX2 AVPR2
3 wolfram syndrome 33.9 WFS1 INS CRH CISD2 AVP
4 diabetes insipidus, nephrogenic, autosomal 33.6 SLC12A1 REN OXT CLCNKA AVPR2 AVPR1B
5 wolfram syndrome 1 33.6 WFS1 INS CRH CISD2 AVP
6 hydronephrosis 31.4 WFS1 SLC12A1 REN AQP2
7 germinoma 31.2 PRL AVP AFP
8 lymphocytic hypophysitis 31.1 POMC GH1
9 nephrogenic syndrome of inappropriate antidiuresis 31.0 AVPR2 AVP
10 secondary adrenal insufficiency 30.9 INS AVP
11 craniopharyngioma 30.9 PRL INS GH1
12 pituitary hormone deficiency, combined, 2 30.8 PRL POMC GH1 AVP
13 lung oat cell carcinoma 30.7 POMC AVP
14 bartter disease 30.7 SLC12A1 REN CLCNKA AVP AQP2
15 pituitary tumors 30.6 PRL POMC GH1
16 polycystic kidney disease 30.6 REN AVPR2 AVP AQP2
17 familial glucocorticoid deficiency 30.5 REN POMC CRH
18 amenorrhea 30.5 PRL POMC INS CRH
19 hypopituitarism 30.5 PRL POMC INS GH1 CRH
20 pituitary adenoma 30.5 PRL POMC GH1 CRH
21 bartter syndrome, type 1, antenatal 30.5 SLC12A1 AQP2
22 central pontine myelinolysis 30.4 AVPR2 AVP AQP2
23 adenohypophysitis 30.4 PRL POMC GH1
24 septooptic dysplasia 30.4 PRL POMC GH1 AVP
25 bipolar disorder 30.4 WFS1 PRL CRH AVPR1B AVPR1A
26 hypothyroidism 30.3 REN PRL POMC INS GH1
27 acute adrenal insufficiency 30.3 REN POMC
28 cranial nerve palsy 30.3 PRL POMC AVP
29 empty sella syndrome 30.3 PRL POMC INS GH1
30 hypoaldosteronism 30.3 REN POMC
31 hypokalemia 30.3 SLC12A1 REN POMC INS CRH AVPR2
32 primary hyperparathyroidism 30.3 PRL POMC INS
33 hyperprolactinemia 30.3 PRL POMC INS GH1
34 adenoma 30.3 REN PRL POMC GH1 CRH
35 liver cirrhosis 30.2 REN AVP AQP2 AFP
36 idiopathic edema 30.2 INS AQP2
37 gitelman syndrome 30.2 SLC12A1 REN CLCNKA
38 pre-eclampsia 30.2 REN OXT INS CRH AFP
39 abducens nerve disease 30.1 PRL POMC
40 pituitary gland disease 30.1 PRL POMC INS GH1 CRH AVP
41 sheehan syndrome 30.1 PRL POMC INS CRH AVP
42 chromophobe adenoma 30.1 PRL POMC GH1
43 pituitary apoplexy 30.1 PRL POMC INS GH1 AVP
44 hypoglycemic coma 30.0 POMC INS
45 hypoglycemia 30.0 PRL POMC INS GH1 CRH
46 pituitary adenoma, prolactin-secreting 30.0 PRL POMC GH1
47 mental depression 30.0 POMC OXT CRH
48 impotence 30.0 PRL POMC OXT INS
49 oligohydramnios 30.0 REN OXT AQP3 AFP
50 gigantism 29.9 PRL GH1

Comorbidity relations with Diabetes Insipidus via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypothyroidism Pituitary Hormone Deficiency, Combined, 2

Graphical network of the top 20 diseases related to Diabetes Insipidus:



Diseases related to Diabetes Insipidus
Sources

Symptoms & Phenotypes for Diabetes Insipidus

About this section

MGI Mouse Phenotypes related to Diabetes Insipidus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 AFP AQP2 AQP3 AVP AVPR1A AVPR1B
2 homeostasis/metabolism MP:0005376 10.25 AFP AQP2 AQP3 AVP AVPR1A AVPR1B
3 growth/size/body region MP:0005378 10.15 AQP2 AQP3 AVPR2 CISD2 CLCNKA CRH
4 endocrine/exocrine gland MP:0005379 10.1 AFP AVPR1A AVPR1B CISD2 CRH INS
5 mortality/aging MP:0010768 9.97 AFP AQP2 AQP3 AVP AVPR2 CISD2
6 integument MP:0010771 9.96 AQP2 AVPR2 CISD2 CRH INS OXT
7 nervous system MP:0003631 9.7 AVP AVPR1A AVPR1B CISD2 CRH INS
8 renal/urinary system MP:0005367 9.4 AQP2 AQP3 AVP AVPR2 CISD2 CLCNKA
Sources

Drugs & Therapeutics for Diabetes Insipidus

About this section

Drugs for Diabetes Insipidus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Lithium carbonate Approved Phase 4 554-13-2
6
Tolvaptan Approved Phase 4 150683-30-0 216237
7 Analgesics, Non-Narcotic Phase 4
8 Analgesics Phase 4
9 Adrenergic Agents Phase 4
10 Adrenergic alpha-Agonists Phase 4
11 Hydrocortisone 17-butyrate 21-propionate Phase 4
12 Hydrocortisone hemisuccinate Phase 4
13 Adrenergic Agonists Phase 4
14 Deamino Arginine Vasopressin Phase 4
15 Hypnotics and Sedatives Phase 4
16 Anesthetics Phase 4
17 Anti-Anxiety Agents Phase 4
18 Anesthetics, General Phase 4
19 GABA Modulators Phase 4
20 Anesthetics, Intravenous Phase 4
21 Neurotransmitter Agents Phase 4
22 Pharmaceutical Solutions Phase 4
23 Psychotropic Drugs Phase 4
24 Antidepressive Agents Phase 4
25 Hormones Phase 4
26 diuretics Phase 4
27
Satavaptan Investigational Phase 3 185913-78-4 7029
28
Atorvastatin Approved Phase 2 134523-00-5 60823
29
Dulaglutide Approved, Investigational Phase 2 923950-08-7
30
tannic acid Approved Phase 2 1401-55-4
31
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
32
Dantrolene Approved, Investigational Phase 1, Phase 2 7261-97-4 6914273 2952
33 Hypolipidemic Agents Phase 2
34 Anticholesteremic Agents Phase 2
35 Lipid Regulating Agents Phase 2
36 Antimetabolites Phase 2
37 Hypoglycemic Agents Phase 2
38 Glucagon-Like Peptide 1 Phase 2
39 Omega 3 Fatty Acid Phase 2
40 Vasopressins Phase 1, Phase 2
41 Arginine Vasopressin Phase 1, Phase 2
42 Hemostatics Phase 1, Phase 2
43 Coagulants Phase 1, Phase 2
44 Vasoconstrictor Agents Phase 1, Phase 2
45
Arginine Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
46
Metformin Approved Phase 1 657-24-9 14219 4091
47
Exenatide Approved, Investigational 141758-74-9 15991534
48
Chlorothiazide Approved, Vet_approved 58-94-6 2720
49
Chlorpropamide Approved, Investigational 94-20-2 2727
50
Epinephrine Approved, Vet_approved 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 The Effect of Midazolam Premedication on Copeptine Concentration in Blood Completed NCT03474939 Phase 4 Midazolam Oral Tablet
3 Pilot Study of the Relationship of Ambient Copeptin to the Aquaretic Effects of Tolvaptan in Patients With Heart Failure Completed NCT01346072 Phase 4 tolvaptan
4 1-deamino 8-d-arginine Vasopressin in Percutaneous Ultrasound-guided Renal Biopsy: a Randomized Controlled Trial Completed NCT00748072 Phase 4 DDAVP;saline solution
5 Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity Completed NCT00902655 Phase 4 Desmopressin
6 Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder: A Randomized Controlled Trial Recruiting NCT04222816 Phase 4 Lithium Carbonate;Sodium chloride
7 Tolvaptan Treatment to Reverse Worsening Outpatient Heart Failure: Possible Role of Copeptin In Identifying Responders (TROUPER) Enrolling by invitation NCT02476409 Phase 4 tolvaptan
8 Acute Heart Failure With High Copeptin Levels Treated With Tolvaptan Targets Increased AVP Activation for Treatment Efficacy Unknown status NCT01733134 Phase 3 Tolvaptan;placebo
9 A CLINICAL STUDY TO EVALUATE THE EFFICACY OF CAUSTICUM 200C IN THE TREATMENT OF PRIMARY ENURESIS Unknown status NCT02154152 Phase 3 Homoeopathic Medicine causticum 200c
10 Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese Patients Completed NCT01280188 Phase 3 Desmopressin Oral Melt;Desmopressin intranasal
11 A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264927 Phase 3 SR121463B
12 An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264914 Phase 3 SR121463B
13 A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Completed NCT03048747 Phase 3 Tolvaptan Oral Tablet
14 Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial Unknown status NCT02967653 Phase 2 Atorvastatin
15 A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT02009878 Phase 1, Phase 2 tolvaptan
16 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion. Completed NCT00032734 Phase 2 satavaptan (SR121463B)
17 Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: "The GOLD-Study" Completed NCT02770885 Phase 2 Dulaglutide;Placebo
18 Efficacy and Pharmacokinetics of Oral Thyroid Replacement Therapy in Organ Donors Completed NCT00238030 Phase 1, Phase 2 L-thryoxine;iv thryoxine
19 A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia Completed NCT01656239 Phase 2 fedovapagon 1 mg;fedovapagon 2 mg;fedovapagon 4 mg;Placebo ( sugar pill)
20 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock Completed NCT01611935 Phase 2 Vasopressin
21 Effects of Glucose Containing Fluid in the Treatment of Acute Dehydration Completed NCT01285713 Phase 2 5% Dextrose (D5) in Normal Saline (NS);Normal Saline (NS)
22 A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder Completed NCT04210804 Phase 2
23 A Phase 1b/2a Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome Recruiting NCT02829268 Phase 1, Phase 2 dantrolene sodium
24 The Influence of Vasopressin on Observational Learning of Placebo Analgesia Recruiting NCT03446456 Phase 1, Phase 2 Arginine vasopressin
25 A Randomised, Double-blind, Placebo-controlled, Five-way Cross-over Dose Response Study to Determine the Effect of VA106483 on Nocturnal Urine Volume in Elderly Male Subjects With Nocturia and Benign Prostatic Hypertrophy (BPH) Completed NCT01330927 Phase 1 VA106483
26 Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI) Terminated NCT02460354 Phase 1 Metformin
27 Study of Novel Types of Familial Diabetes Insipidus Unknown status NCT00004364 desmopressin
28 GLP Analogs for Diabetes in Wolfram Syndrome Patients Unknown status NCT01302327 Exenatide
29 Evaluation of Copeptin in Patients With Cirrhosis and Ascites Unknown status NCT03318601
30 Diagnostic Utility of Copeptin in Addition to High-sensitivity Cardiac Troponin for the Early Diagnosis of Non-ST-Elevation Acute Coronary Syndromes - The COPACS Study Unknown status NCT01962506
31 CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS: EVIDENCE OF GLUCOSE METABOLISM ABNORMALITIES Unknown status NCT00483925
32 Study of Prognostic Value of Copeptin for Myocardial Infarct Size and 6-month Prognosis in Patients With ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: GOOD I Study Unknown status NCT03074214
33 Skull Base Reconstruction After Endonasal Cranio-endoscopic Resection Using Autologus Grafts Unknown status NCT03448614
34 Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study Completed NCT00757276
35 Copeptin After Arginine Infusion for the Differential Diagnosis of the Polyuria-Polydipsia Syndrome ''The CARGO-Study'' Completed NCT01879137
36 Use of Copeptin in the Differential Diagnosis of Diabetes insipidus-a Prospective International Study Completed NCT01940614
37 Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed NCT00004360 chlorothiazide
38 Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed NCT00004363 chlorpropamide;desmopressin
39 The Circadian Rhythm of Copeptin Completed NCT02604875
40 Copeptin During a Standardized Psychological Stress Test Completed NCT01866137
41 Kinetics of Copeptin in Healthy Volunteers - a Prospective International Study Completed NCT02647736
42 Copeptin as a Stress Marker During a Written Examination - the CoEXAM Completed NCT02051647
43 GE DHM-AN-OR-2012/01 Completed NCT01648647
44 Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis Completed NCT01465672
45 Copeptin During a Standardized Oral Glucose Tolerance Test and a Mixed Meal Tolerance Test Completed NCT01772914
46 Copeptin in Differentiation of Polyuria and Polydipsia Completed NCT01056887
47 Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion Completed NCT00696605
48 Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers - The Macicop-Study Completed NCT03844217 Macimorelin 0.5mg/kg body weight;Macimorelin 0.75mg/kg body weight
49 Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus Completed NCT00478335 sildenafil;calcitonin;hydrochlorothiazide/amiloride;indomethacin;Placebo for sildenafil;placebo for calcitonin
50 Vasopressin Deficiency in Hemorrhagic Shock Completed NCT01107314

Search NIH Clinical Center for Diabetes Insipidus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


desmopressin
Desmopressin Acetate
Vasopressin (USP)
VASOPRESSIN TANNATE (IN OIL)

Cochrane evidence based reviews: diabetes insipidus

Sources

Genetic Tests for Diabetes Insipidus

About this section

Genetic tests related to Diabetes Insipidus:

# Genetic test Affiliating Genes
1 Diabetes Insipidus 29
Sources

Anatomical Context for Diabetes Insipidus

About this section

MalaCards organs/tissues related to Diabetes Insipidus:

40
Pituitary, Brain, Kidney, Testes, Lung, Thyroid, Liver
Sources

Publications for Diabetes Insipidus

About this section

Articles related to Diabetes Insipidus:

(show top 50) (show all 8469)
# Title Authors PMID Year
1
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of diabetes insipidus and hyponatraemia. 61 42
32380474 2020
2
Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics. 61 42
31928727 2019
3
Clinical and genetic analysis of two wolfram syndrome families with high occurrence of wolfram syndrome and diabetes type II: a case report. 42
31937257 2020
4
Effect of Arginine on the Hypothalamic-Pituitary-Adrenal Axis in Individuals With and Without Vasopressin Deficiency. 61
32236441 2020
5
Letter to the Editor: "Forty-One Individuals With Mutations in the AVP-NPII Gene Associated With Familial Neurohypophyseal Diabetes Insipidus." 61
32392320 2020
6
Response to Letter to the Editor: "Forty-One Individuals with Mutations in the AVP-NPII Gene Associated with Familial Neurohypophyseal Diabetes Insipidus. 61
32392319 2020
7
Long-term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan. 61
32383820 2020
8
Central diabetes insipidus and pituitary stalk thickening in adults: distinction of neoplastic from non-neoplastic lesions. 61
32530258 2020
9
Refractory Inflammatory Bowel Disease Associated With Sclerosing Cholangitis, Diabetes Insipidus, and Myeloid Neoplasm: Langerhans Cell Histiocytosis Was Hiding Since the Beginning. 61
32530029 2020
10
Endometrial adenocarcinoma metastatic to the pituitary gland: a case report and literature review. 61
32500767 2020
11
Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy. 61
32244049 2020
12
Role of 18F-fluorodeoxyglucose (FDG) and 18F-2-fluorodeoxy sorbitol (FDS) in autoimmune hypophysitis: a case report. 61
32517690 2020
13
Pituitary tumors: epidemiology and clinical presentation spectrum. 61
31933100 2020
14
Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. 61
32507965 2020
15
Foscarnet-Associated Nephrogenic Diabetes Insipidus. 61
32568860 2020
16
Impurity identification and quantification for arginine vasopressin by liquid chromatography/high-resolution mass spectrometry. 61
32247289 2020
17
Complete Microsurgical Resection of Large Retrochiasmatic Hypothalamic Craniopharyngioma by Transpetrosal Approach: 2-Dimensional Operative Video. 61
31538198 2020
18
INCIDENTAL FINDINGS ON BRAIN MAGNETIC RESONANCE IMAGING (MRI) IN PEDIATRIC ENDOCRINE PATIENTS. 61
32576030 2020
19
A homozygote frameshift mutation in OCLN gene result in Pseudo-TORCH syndrome type I: A case report extending the phenotype with central diabetes insipidus and renal dysfunction. 61
32240828 2020
20
Real-life analysis of 280 patients with surgically treated acromegaly: a single-center experience from 2008 to 2015. 61
32480363 2020
21
Pituitary metastases: presentation and outcomes from a pituitary center over the last decade. 61
32189207 2020
22
Effects of extreme potassium stress on blood pressure and renal tubular sodium transport. 61
32281415 2020
23
Recurrence of Rathke's cleft cysts based on gross total resection of cyst wall: a meta-analysis. 61
31041618 2020
24
Predicting prolonged length of stay after endoscopic transsphenoidal surgery for pituitary adenoma. 61
32362064 2020
25
Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. 61
32480370 2020
26
Diabetes Insipidus After Endoscopic Transsphenoidal Surgery. 61
32503055 2020
27
Challenges, Learning Curve, and Safety of Endoscopic Endonasal Surgery of Sellar-Suprasellar Lesions in a Community Hospital. 61
32298827 2020
28
A 52-Year-Old Man With Cough, Dyspnea, and Diffuse Parenchymal Lung Disease for 5 Years. 61
32505326 2020
29
3-D endoscopy in surgery of pituitary adenomas, prospective evaluation of patient gain using basic outcome parameters. 61
32253144 2020
30
Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics. 61
32573959 2020
31
Low arginine vasopressin levels in patients with diabetes insipidus are not associated with anaemia. 61
32534481 2020
32
Analysis of 2141 pediatric craniopharyngioma admissions in the USA utilizing the Kids' Inpatient Database (KID): predictors of discharge disposition. 61
32363544 2020
33
Traumatic brain injuries induced pituitary dysfunction: a call for algorithms. 61
32412425 2020
34
Report: central diabetes insipidus and schwannoma in a male with X-linked congenital adrenal hypoplasia. 61
32460754 2020
35
Symptomatic Cerebral Vasospasm After Transsphenoidal Tumor Resection: Two Case Reports and Systematic Literature Review. 61
32566415 2020
36
Takotsubo cardiomyopathy and pituitary apoplexy: a case report. 61
32429846 2020
37
Hypertrophic cardiomyopathy and nephrogenic diabetes insipidus associated with chronic lithium carbonate use. 61
32535507 2020
38
Secondary oxalosis induced by xylitol concurrent with lithium-induced nephrogenic diabetes insipidus: a case report. 61
32357847 2020
39
Endocrinological Features of Hartsfield Syndrome in an Adult Patient With a Novel Mutation of FGFR1. 61
32373773 2020
40
Epac1 null mice have nephrogenic diabetes insipidus with deficient corticopapillary osmotic gradient and weaker collecting duct tight junctions. 61
31943825 2020
41
A female with X-linked Nephrogenic diabetes insipidus in a family with inherited central diabetes Insipidus: Case report and review of the literature. 61
32073219 2020
42
Copeptin-based diagnosis of diabetes insipidus. 61
32374887 2020
43
Chloroquine attenuates lithium-induced NDI and proliferation of renal collecting duct cells. 61
32249612 2020
44
Sorting Nexin 27 Regulates the Lysosomal Degradation of Aquaporin-2 Protein in the Kidney Collecting Duct. 61
32413996 2020
45
Ultrasensitive and Highly Selective Graphene-Based Field-Effect Transistor Biosensor for Anti-Diuretic Hormone Detection. 61
32384631 2020
46
Prevalence of Endocrine and Metabolic Comorbidities in a National Cohort of Patients with Craniopharyngioma. 61
32460296 2020
47
A homozygous missense mutation of WFS1 gene causes Wolfram's syndrome without hearing loss in an Iranian family (a report of clinical heterogeneity). 61
32419160 2020
48
Adult craniopharyngioma: The role of extent of resection in tumor recurrence and long-term functional outcome. 61
32036264 2020
49
Optimisation of the organ donor and effects on transplanted organs: a narrative review on current practice and future directions. 61
32430910 2020
50
Transient water-electrolyte disturbance after hemispherotomy in young infants with epileptic encephalopathy. 61
31845027 2020
Sources

Variations for Diabetes Insipidus

About this section

ClinVar genetic disease variations for Diabetes Insipidus:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MATN4 NM_003833.4(MATN4):c.515G>C (p.Gly172Ala)SNV Likely pathogenic 183295 rs730882210 20:43932996-43932996 20:45304356-45304356
Sources

Expression for Diabetes Insipidus

About this section
Search GEO for disease gene expression data for Diabetes Insipidus.
Sources

Pathways for Diabetes Insipidus

About this section

Pathways related to Diabetes Insipidus according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 13.26 PRL POMC OXT GH1 CRH AVPR2
2
Glucose / Energy Metabolism 4
12.29 WFS1 INS CISD2 AQP2
3
Oxytocin signaling pathway 36
Show member pathways
 12.24 OXT AVPR1B AVPR1A AVP
4
Aquaporin-mediated transport 65
Show member pathways
 12.17 AVPR2 AVP AQP3 AQP2
5
Phospholipase D signaling pathway 36
Show member pathways
 11.94 INS AVPR2 AVPR1B AVPR1A AVP
6
Peptide hormone metabolism 65
Show member pathways
 11.93 REN POMC INS GH1
7
G alpha (s) signalling events 65
11.72 POMC CRH AVPR2 AVP
8
Glucocorticoid receptor regulatory network 1
11.52 PRL POMC AFP
9
Vasopressin-regulated water reabsorption 36
10.57 AVPR2 AVP AQP3 AQP2
10
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.43 PRL POMC INS
11
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 60
10.25 POMC CRH
Sources

GO Terms for Diabetes Insipidus

About this section

Cellular components related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 REN PRL POMC OXT NPTX2 INS
2 extracellular space GO:0005615 9.61 REN PRL POMC OXT INS GH1
3 secretory granule GO:0030141 9.43 POMC OXT AVP
4 endosome lumen GO:0031904 8.8 PRL INS GH1

Biological processes related to Diabetes Insipidus according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.1 POMC OXT INS CRH AVPR2 AVPR1B
2 signal transduction GO:0007165 10.06 PRL POMC OXT INS GH1 CRH
3 positive regulation of cell proliferation GO:0008284 10.01 PRL INS CRH AVPR2 AVPR1A AVP
4 cellular protein metabolic process GO:0044267 9.95 WFS1 PRL INS AFP
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.88 OXT AVPR1B AVPR1A AVP
6 female pregnancy GO:0007565 9.83 PRL OXT CRH
7 positive regulation of cell growth GO:0030307 9.83 INS AVPR1A AVP
8 social behavior GO:0035176 9.79 OXT AVPR1A AVP
9 generation of precursor metabolites and energy GO:0006091 9.79 POMC AVPR1A AVP
10 cellular response to hormone stimulus GO:0032870 9.76 AVPR2 AVPR1B AVPR1A
11 response to corticosterone GO:0051412 9.67 CRH AVPR1A
12 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.67 PRL GH1
13 positive regulation of renal sodium excretion GO:0035815 9.66 OXT AVPR1A
14 positive regulation of growth GO:0045927 9.65 WFS1 GH1
15 positive regulation of blood pressure GO:0045777 9.65 OXT AVPR2 AVPR1A
16 positive regulation of glutamate secretion GO:0014049 9.64 AVPR1A AVP
17 drinking behavior GO:0042756 9.64 REN OXT
18 glycerol transport GO:0015793 9.63 AQP3 AQP2
19 hyperosmotic salinity response GO:0042538 9.63 OXT AVP
20 water transport GO:0006833 9.63 AVP AQP3 AQP2
21 positive regulation of prostaglandin biosynthetic process GO:0031394 9.62 AVPR1A AVP
22 negative regulation of transmission of nerve impulse GO:0051970 9.61 AVPR1A AVP
23 grooming behavior GO:0007625 9.61 OXT AVPR1A AVP
24 sperm ejaculation GO:0042713 9.6 OXT AVPR1A
25 negative regulation of urine volume GO:0035811 9.59 OXT AVPR2
26 maternal behavior GO:0042711 9.58 OXT AVPR1A AVP
27 response to ether GO:0045472 9.57 OXT CRH
28 positive regulation of cellular pH reduction GO:0032849 9.56 AVPR1A AVP
29 positive regulation of vasoconstriction GO:0045907 9.56 AVPR2 AVPR1B AVPR1A AVP
30 negative regulation of female receptivity GO:0007621 9.55 AVPR1A AVP
31 positive regulation of systemic arterial blood pressure GO:0003084 9.54 AVPR2 AVPR1A AVP
32 penile erection GO:0043084 9.52 AVPR1A AVP
33 cellular response to water deprivation GO:0042631 9.51 AVPR1A AQP2
34 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.33 AVPR2 AVPR1B AVPR1A
35 maternal aggressive behavior GO:0002125 9.13 OXT AVPR1A AVP
36 renal water homeostasis GO:0003091 9.02 WFS1 AVPR2 AVP AQP3 AQP2

Molecular functions related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.58 AVPR2 AVPR1B AVPR1A
2 neuropeptide hormone activity GO:0005184 9.54 OXT CRH AVP
3 insulin-like growth factor receptor binding GO:0005159 9.46 REN INS
4 water channel activity GO:0015250 9.43 AQP3 AQP2
5 V1A vasopressin receptor binding GO:0031894 9.32 AVPR1A AVP
6 neurohypophyseal hormone activity GO:0005185 9.26 OXT AVP
7 hormone activity GO:0005179 9.17 PRL POMC OXT INS GH1 CRH
8 prolactin receptor binding GO:0005148 9.16 PRL GH1
9 vasopressin receptor activity GO:0005000 9.13 AVPR2 AVPR1B AVPR1A
Sources

Sources for Diabetes Insipidus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....